Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioTime launches all-stock bid to acquire Geron's stalled stem cell programme

This article was originally published in Clinica

Executive Summary

After hiring Geron's former president and CEO to run an acquisition-focused subsidiary, BioTime has made a public bid for the regenerative medicine programme that Geron put on hold almost a year ago, offering an all-stock deal for embryonic stem cell technology previously investigated as a treatment for acute spinal cord injuries.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel